Clinical trials on Essential Thrombocythemia

Essential thrombocythemia (ET) is a rare chronic blood disorder, part of a group known as myeloproliferative neoplasms. In this condition, the bone marrow produces an excessive number of platelets, which can lead to blood clotting or bleeding problems. Patients with ET might experience symptoms like headaches, dizziness, and visual disturbances or might have no symptoms at all, only to be diagnosed through routine blood tests. The main concern is the risk of developing clots or hemorrhages due to the abnormal platelet count.


  • Thrombosis: High platelet counts can lead to the formation of blood clots in arteries or veins, potentially causing strokes, heart attacks, or deep vein thrombosis.
  • Bleeding: Despite the high platelet count, the platelets may not function properly, leading to unexpected bleeding, such as nosebleeds or gum bleeding.
  • Progression to myelofibrosis: Over time, ET can evolve into myelofibrosis, a condition where the bone marrow becomes scarred, reducing its ability to produce blood cells.
  • Transformation to acute leukemia: There is a small risk that ET can transform into acute myeloid leukemia (AML), a more aggressive form of blood cancer.
  • Enlarged spleen (splenomegaly): As the spleen works to filter abnormal cells, it can become enlarged, causing discomfort and affecting digestive functions.

Treatment Methods

  • Low-dose aspirin: Often used to reduce the risk of clotting in patients with mildly elevated platelet counts who have low-risk profiles.
  • Hydroxyurea: A chemotherapy agent used to lower platelet counts in high-risk patients, reducing the risk of thrombosis.
  • Anagrelide: Specifically targets the reduction of platelet production, used when patients cannot tolerate or do not respond well to hydroxyurea.
  • Interferon-alpha: A treatment that stimulates the immune system to help control platelet production, suitable for younger patients or those planning pregnancy.
  • JAK inhibitors: In cases where ET is associated with a JAK2 mutation, these drugs can help manage symptoms and control platelet levels.


The prognosis for patients with essential thrombocythemia varies based on age, health status, and response to treatment. With appropriate management, many patients lead normal or near-normal lifespans. Treatment primarily aims to prevent complications such as thrombosis and to manage symptoms effectively. In the absence of treatment, the risks of serious complications such as stroke or major bleeding events increase significantly. Regular monitoring and personalized treatment strategies are essential to maintain a good quality of life and to minimize the risk of the disease progressing to more severe conditions like myelofibrosis or acute leukemia.
  • CT-EU-00115682

    Exploring the Safety and Dosage of JNJ-88549968 for CALR-Mutated Blood Disorders

    A study is being introduced that focuses on a new treatment option, JNJ-88549968, for patients with Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms. The aim is to explore the safety and effectiveness of JNJ-88549968 and to determine the best dose and schedule for treatment.

    In the first part of the study, the dose of JNJ-88549968 will be gradually increased to identify the safest and most effective level. Close monitoring for any side effects, particularly those that are severe or unexpected, will be conducted to ensure the highest level of safety for participants.

    The second part of the study will continue to evaluate the safety of JNJ-88549968 at the recommended dose. Attention will be given to how participants respond to the treatment and any side effects they experience. The severity of any side effects will be carefully graded to better understand the treatment’s impact.

    This study represents a significant advancement in the search for new treatments for Myeloproliferative Neoplasms. Participation will contribute valuable information that could potentially improve the lives of others with these conditions in the future.

    • JNJ-88549968
  • Study on new drug effects in treating blood disorder

    In this study, the drug being investigated is INCA033989. It will be given alone or in combination with ruxolitinib in people with a condition known as myeloproliferative neoplasms. The primary goal of the research is to assess safety, comfort, and the occurrence of possible harmful effects, especially at specific dosages. Additionally, doctors will try to determine the highest dose participants can tolerate without serious side effects. Importantly, observations will be made regarding any changes in the disease or participants’ subjective experiences.

    • INCA033989- new potential medication for myelofibrosis (MF) and essential thrombocythemia (ET)
    • Ruxolitinib